Thermo Fisher Scientific Inc. $TMO Stock: James Hambro & Partners LLP Increases Stake

James Hambro & Partners LLP lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 231,390 shares of the medical research company’s stock after purchasing an additional 1,919 shares during the quarter. Thermo Fisher Scientific accounts for about 5.4% of James Hambro & Partners LLP’s portfolio, making the stock its 9th biggest position. James Hambro & Partners LLP’s holdings in Thermo Fisher Scientific were worth $156,260,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of TMO. Bank OZK bought a new position in Thermo Fisher Scientific in the second quarter valued at approximately $1,096,000. Ausdal Financial Partners Inc. acquired a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $456,000. BlackRock Inc. bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $15,501,867,000. German American Bancorp Inc. bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $4,920,000. Finally, Parallax Volatility Advisers L.P. acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth $814,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $77,982,284.75. This represents a 7.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on TMO. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Piper Sandler started coverage on Thermo Fisher Scientific in a report on Wednesday, September 9th. They issued an “overweight” rating on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $630.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Wells Fargo & Company downgraded Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a report on Wednesday, September 9th. Finally, Scotiabank assumed coverage on Thermo Fisher Scientific in a research report on Wednesday, September 9th. They issued an “outperform” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $654.05.

Thermo Fisher Scientific Stock Down 1.7%

Shares of Thermo Fisher Scientific stock traded down $11.61 during trading hours on Monday, reaching $678.39. 972,382 shares of the company’s stock were exchanged, compared to its average volume of 2,248,104. The stock has a market cap of $250.83 billion, a P/E ratio of 36.48, a P/E/G ratio of 2.89 and a beta of 0.87. The company has a 50 day moving average of $637.32 and a two-hundred day moving average of $548.58. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $704.00.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the previous year, the business earned $4.28 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.